Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 04:00:45 2024-05-14 pm EDT			After market 05:13:59 pm
128.7 ^USD	-0.49%		128.5	-0.14%

02:36pm	US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine	RE
May. 13	Merck: phase 3 trial in melanoma halted	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	01:16am	AQ
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma	May. 13	BU
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA plus Chemotherapy, With or Without Radiotherapy, for Patients with Newly Diagnosed, High-Risk Endometrial Cancer	May. 10	AQ
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy	May. 09	AQ
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent	May. 09	BU
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers	May. 08	AQ
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference	May. 08	BU
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	May. 01	BU
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults	Apr. 29	BU
Merck: Q1 Earnings Snapshot	Apr. 25	AQ
Merck Announces First-Quarter 2024 Financial Results	Apr. 25	BU
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy	Apr. 19	AQ
Merck Manuals Celebrates Its 125th Year	Apr. 17	AQ
Moderna cancer vaccine shows promise in initial tests; share skyrockets	Apr. 12	AQ
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer	Apr. 05	AQ
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer	Apr. 04	BU
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	Apr. 03	AQ
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	BU
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	Apr. 02	AQ
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25	Apr. 01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Press Releases

Filters